LONDON, Nov 5 (Reuters) - Novo Nordisk said on Wednesday

it has accepted the U.S. Inflation Reduction Act (IRA)'s maximum

fair price for its diabetes and obesity medicines Ozempic,

Wegovy and Rybelsus, which will become effective in January

2027.

Novo made the disclosure in its quarterly earnings report.

The price negotiation process was established under

President Biden's signature IRA in 2022.

Novo's drugs are among 15 selected as the second group of

medications undergoing the process, and are among the most

expensive for the Medicare health program for people aged 65 and

older or with disabilities.